Prepared by Dr. David Miller, CFA, Director of US Markets | Reviewed by Anna Kowalski, Lead Editor | Report ID: IGEMINI-04FD1C49-20260531 | Data as of 2026-05-31
Executive Summary: Our multi-factor model assigns cardiff oncology stock a Bullish outlook for the next quarter. Key drivers include a P/E of 48.91x, 37.7% revenue expansion, and an RSI of 30 suggesting a neutral-bullish phase. We define critical support at $19332 and resistance at $23628.
Rating: Outperform | Target Price: $27064.8 | Next Earnings: Jul 02
Download Full PDF Report
Price action carved a Ascending Triangle, confirmed by a 0.61x volume spike on May 05, 2026. The resistance at $19332 was tested.
Ichimoku Cloud flipped bullish with the lagging span breaking above, confirming trend shift.
Relative to Utilities peers, cardiff oncology stock sits at the 77th percentile in valuation, offering a potential value opportunity.
EPS of $439.17 reveals above-sector earnings quality. DuPont analysis highlights asset turnover as the key ROE driver.
Dark pool prints show a 33%% surge in block trades, indicating institutional accumulation before Jul 02 earnings.
Short float at 3% is below the sector average, reducing squeeze risk. Institutional ownership is 73%.
Beta of 0.79 suggests cardiff oncology stock is {beta_desc} volatile than the market, influencing hedging strategies.
| Metric | Value | Sector Avg |
|---|---|---|
| Last Price | $21480 | $20406 |
| Market Cap | $22.84B | $22.84B |
| P/E Ratio | 48.91x | 41.6x |
| EPS (TTM) | $439.17 | $395.25 |
| Dividend Yield | 5.92% | 4.1% |
| Revenue Growth | 37.7% | 22.6% |
| Target Price | $27064.8 | - |
| Beta | 0.79 | 1.00 |